tradingkey.logo
tradingkey.logo

Merck boosts cancer portfolio with $6.7 billion buyout of Terns Pharma

ReutersMar 25, 2026 10:48 AM

- Merck MRK.N said on Wednesday it would buy biotech Terns Pharma TERN.O in a deal valued at up to $6.7 billion, as the drugmaker races to bolster its cancer pipeline ahead of the looming patent loss for its blockbuster therapy Keytruda.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey

Recommended Articles

Tradingkey
KeyAI